ABLD Stock Overview
ABL Diagnostics Société anonyme provides proprietary molecular biology assays and end-to-end solutions to be used for molecular detection by polymerase chain reaction (PCR) and through DNA sequencing in France and internationally.
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 0/6 |
Past Performance | 1/6 |
Financial Health | 4/6 |
Dividends | 0/6 |
ABL Diagnostics Société anonyme Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | €3.18 |
52 Week High | €9.70 |
52 Week Low | €3.18 |
Beta | -0.16 |
1 Month Change | -67.22% |
3 Month Change | -67.22% |
1 Year Change | n/a |
3 Year Change | 27.20% |
5 Year Change | -20.00% |
Change since IPO | 195.88% |
Recent News & Updates
Recent updates
Shareholder Returns
ABLD | FR Trade Distributors | FR Market | |
---|---|---|---|
7D | 0% | 3.8% | -0.4% |
1Y | n/a | 14.1% | 10.6% |
Return vs Industry: Insufficient data to determine how ABLD performed against the French Trade Distributors industry.
Return vs Market: Insufficient data to determine how ABLD performed against the French Market.
Price Volatility
ABLD volatility | |
---|---|
ABLD Average Weekly Movement | 18.9% |
Trade Distributors Industry Average Movement | 3.5% |
Market Average Movement | 4.3% |
10% most volatile stocks in FR Market | 10.0% |
10% least volatile stocks in FR Market | 2.2% |
Stable Share Price: ABLD's share price has been volatile over the past 3 months.
Volatility Over Time: ABLD's weekly volatility has increased from 14% to 19% over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
n/a | 21 | Ronan Boulme | https://www.abldiagnostics.com |
ABL Diagnostics Société anonyme provides proprietary molecular biology assays and end-to-end solutions to be used for molecular detection by polymerase chain reaction (PCR) and through DNA sequencing in France and internationally. It offers genotyping through NGS and sanger sequencing for human immunodeficiency virus, SARS CoV-2, hepatitis-C virus, mycobacterium tuberculosis, and 16S RNA; ultragene assays for viral detection of SARS CoV-2, dengue, and Zika virus; microbiological specimen transport and collection kits, which include RNA and saliva preservation, wastewater collection, and surface collection kits, as well as inactivation and preservation solution; and instrument and consumables, such as DNA/RNA extraction system, real-time PCR system, liquid handling robot, NGS library preparation system, and sanger sequencing reagents. The company also provides digital solutions comprising analysis software, data hosting, lab automation, Nadis, and SeqHepB.
ABL Diagnostics Société anonyme Fundamentals Summary
ABLD fundamental statistics | |
---|---|
Market cap | €51.24m |
Earnings (TTM) | €1.20m |
Revenue (TTM) | €12.26m |
42.6x
P/E Ratio4.2x
P/S RatioIs ABLD overvalued?
See Fair Value and valuation analysisEarnings & Revenue
ABLD income statement (TTM) | |
---|---|
Revenue | €12.26m |
Cost of Revenue | €8.90m |
Gross Profit | €3.36m |
Other Expenses | €2.16m |
Earnings | €1.20m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | 0.075 |
Gross Margin | 27.43% |
Net Profit Margin | 9.81% |
Debt/Equity Ratio | 44.9% |
How did ABLD perform over the long term?
See historical performance and comparison